Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanoporous Particles Deliver Novel Molecular Therapies to Tumors

Abstract:
Using nanoporous silicon particles, two teams of investigators have created drug delivery vehicles capable of ferrying labile molecular therapies deep into the body. Both groups believe their new drug delivery vehicles create new opportunities for developing innovative anticancer therapies.

Nanoporous Particles Deliver Novel Molecular Therapies to Tumors

Bethesda, MD | Posted on May 22nd, 2010

Mauro Ferrari, of the University of Texas Health Sciences Center at Houston, led a research team aiming to develop new methods of delivering therapeutic small interfering RNA (siRNA) molecules to tumors. He and his colleagues published their results of their studies in the journal Cancer Research. Karl Erik Hellstrom, of the University of Washington, and Jun Liu and Chenghong Lei, both of the Pacific Northwest National Laboratory (PNNL), led the research group developing methods for delivering therapeutic antibodies to tumors. Their research was published in the Journal of the American Chemical Society. Dr. Ferrari is the principal investigator of one of the National Cancer Institute's (NCI) Physical Sciences in Oncology Centers, and he played a seminal role in establishing the NCI's Alliance for Nanotechnology in Cancer.

siRNA is promising approach to anticancer therapy, and one anticancer siRNA molecule is now in clinical trials in humans (*). However, siRNA molecules are rapidly degraded in the body, so delivering them to tumors requires help.

Dr. Ferrari's team approached this problem by first encapsulating siRNA molecules in lipid-based nanoparticles. Earlier work by his team had already demonstrated that these lipid nanoparticles could deliver siRNA molecules to tumors, but achieving a therapeutic effect in tumor-bearing mice required twice-weekly injections for many weeks. To reduce the number of injections needed, Dr. Ferrari and his colleagues decided to load their nanoparticle-siRNA construct into the pores of biocompatible nanoporous silicon particles.They then injected their drug delivery vehicle into mice with human ovarian tumors.

When the researchers examined the mice three weeks later, the researchers found that tumors had shrunken markedly and that the siRNA agent was still exerting its biological effect. The investigators also found that toxicities were minimal or non-existent.

Meanwhile, the University of Washington-PNNL team used nanoporous silicon to entrap large numbers of monoclonal antibodies that target a specific tumor-associated protein known as CTLA-4. Monoclonal antibodies targeting CTLA-4 have been shown to produce marked antitumor effects in human clinical trials, but therapeutic levels of this antibody can trigger unwanted autoimmune reactions and other severe side effects. Drs. Hellstrom, Liu, and Lei and their collaborators reasoned that nanoporous silicon particles could act as a reservoir that would maintain therapeutic levels of antibody right at the tumor site while reducing the overall amount of antibody circulating freely in the body.

To test their hypothesis, the investigators injected their construct directly into melanomas growing in mice. As a control, a second set of mice received CTLA-4 monoclonal antibodies injected into the peritoneal cavity. Results of this experiment showed that CTLA-4 monoclonal antibodies delivered using nanoporous silicon produced a month-long suppression of tumor growth with no toxicity, while CTLA-4 antibodies alone had little effect on tumor growth. The first group of animals also lived far longer than the second group.

This work on siRNA is detailed in a paper titled, "Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles." Investigators from the University of Texas M.D. Anderson Cancer Center, Rice University, Baylor College of Medicine, University of Texas at Austin, and the University of Puerto Rico Comprehensive Cancer Center also participated in this study. An abstract of this paper is available at the journal's Web site.

View abstract dx.doi.org/10.1158/0008-5472.CAN-09-3931

This work with antibodies is detailed in a paper titled, "Local Release of Highly Loaded Antibodies from Functionalized Nanoporous Support for Cancer Immunotherapy." An abstract of this paper is available at the journal's Web site.

View abstract dx.doi.org/10.1021/ja102414t

(*) nano.cancer.gov/action/news/2010/apr/nanotech_news_2010-04-16a.asp

####

About NCI Alliance for Nanotechnology in Cancer
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Copyright © NCI Alliance for Nanotechnology in Cancer

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

Possible Futures

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Video captures bubble-blowing battery in action: Researchers propose how bubbles form, could lead to smaller lithium-air batteries April 26th, 2017

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

Geoffrey Beach: Drawn to explore magnetism: Materials researcher is working on the magnetic memory of the future April 25th, 2017

Academic/Education

California Research Alliance by BASF establishes more than 25 research projects in three years April 26th, 2017

SUNY Polytechnic Institute Announces Total of 172 Teams Selected to Compete in Solar in Your Community Challenge: Teams from 40 states, plus Washington, DC, 2 Territories, and 4 American Indian Reservations, Will Deploy Solar in Underserved Communities April 20th, 2017

Rice crew revved for Nanocar Race: Nanocar creator James Tour and team take on international competition with single-molecule marvel April 20th, 2017

The Catholic University of Rome uses the JPK NanoWizard® AFM & CellHesion® systems to understand how cells sense and respond to mechanical stimuli April 5th, 2017

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Announcements

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Video captures bubble-blowing battery in action: Researchers propose how bubbles form, could lead to smaller lithium-air batteries April 26th, 2017

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Nano-SPEARs gently measure electrical signals in small animals: Rice University's tiny needles simplify data gathering to probe diseases, test drugs April 17th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project